Literature DB >> 15018602

Use of medical services by methylphenidate-treated children in the general population.

Anton R Miller1, Jamie C Brehaut, Parminder Raina, Kimberlyn M McGrail, Robert W Armstrong.   

Abstract

OBJECTIVES: To examine selected medical services for children treated for attention-deficit/hyperactivity disorder (ADHD) in a general population setting with universal health insurance.
DESIGN: Retrospective analysis of administrative prescription and health services databases spanning from 1990 to 1996.
SETTING: British Columbia, Canada. PATIENTS: Children (<19 years of age) who had received the psychostimulant methylphenidate (MPH; Ritalin) on a chronic basis (chronic-MPH group), who had received MPH on any other basis (nonchronic-MPH group), and who were in a no-MPH comparison group. MAIN OUTCOME MEASURES: The number of individuals who received any of the following services based on claims submitted by qualified practitioners: 1) emergency care, 2) critical care, 3) injury-related diagnostic and treatment services, 4) complementary and alternative medical (CAM) care, and 5) other diagnostic and treatment services (audiometry and allergy testing).
RESULTS: Prevalence of services users was higher among MPH-treated than nontreated children for all types of services (except critical care services in the chronic-MPH group) after adjusting for effects of age, sex, socioeconomic status, and geographic setting, with odds ratios ranging from 1.49 to 3.17. There were no differences between the 2 MPH-treated groups.
CONCLUSIONS: Children treated with MPH for ADHD or presumed ADHD are more frequent users of a wide range of medical services than are other children. Findings support and extend existing evidence of increased use of medical services by this population of children. Findings have implications for service planning, including injury prevention, with these children. High utilization of audiometric, allergy, and CAM services warrants further scrutiny.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018602     DOI: 10.1367/A03-031R1.1

Source DB:  PubMed          Journal:  Ambul Pediatr        ISSN: 1530-1567


  9 in total

1.  General practitioner-centred paediatric primary care reduces risk of hospitalisation for mental disorders in children and adolescents with ADHD: findings from a retrospective cohort study.

Authors:  Angelina Mueller; Olga A Sawicki; Moritz Philipp Günther; Anastasiya Glushan; Claudia Witte; Renate Klaaßen-Mielke; Ferdinand M Gerlach; Martin Beyer; Kateryna Karimova
Journal:  Eur J Gen Pract       Date:  2022-12       Impact factor: 3.636

2.  Gender and injuries predict stimulant medication use.

Authors:  Søren Dalsgaard; James F Leckman; Helena Skyt Nielsen; Marianne Simonsen
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576

3.  Comparing the frequency of unrecognized attention deficit hyperactivity disorder symptoms in injured versus noninjured patients presenting for care in the pediatric emergency department.

Authors:  Zachary E Pittsenbarger; Jacqueline Grupp-Phelan; Kieran J Phelan
Journal:  Pediatr Emerg Care       Date:  2008-07       Impact factor: 1.454

4.  Nonmedical prescription stimulant use among youth in the emergency department: prevalence, severity and correlates.

Authors:  Lauren K Whiteside; Rebecca M Cunningham; Erin E Bonar; Frederic Blow; Peter Ehrlich; Maureen A Walton
Journal:  J Subst Abuse Treat       Date:  2014-06-10

5.  The relationship between childhood behaviour disorders and unintentional injury events.

Authors:  Beth Bruce; Susan Kirkland; Daniel Waschbusch
Journal:  Paediatr Child Health       Date:  2007-11       Impact factor: 2.253

Review 6.  Parenting interventions for the prevention of unintentional injuries in childhood.

Authors:  Denise Kendrick; Caroline A Mulvaney; Lily Ye; Tony Stevens; Julie A Mytton; Sarah Stewart-Brown
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

7.  A systematic review of global publication trends regarding long-term outcomes of ADHD.

Authors:  Paul Hodgkins; L Eugene Arnold; Monica Shaw; Hervé Caci; Jennifer Kahle; Alisa G Woods; Susan Young
Journal:  Front Psychiatry       Date:  2012-01-18       Impact factor: 4.157

Review 8.  Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Authors:  Christopher Steer; Jan Froelich; César A Soutullo; Mats Johnson; Monica Shaw
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

Review 9.  Attention deficit/hyperactivity disorder and risk of injuries: A systematic review and meta-analysis.

Authors:  Shahrokh Amiri; Homayoun Sadeghi-Bazargani; Soulmaz Nazari; Fatemeh Ranjbar; Salman Abdi
Journal:  J Inj Violence Res       Date:  2016-11-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.